Mutations of ras protooncogenes and p53 tumor suppressor gene in cardiac hemangiosarcomas from B6C3F1 mice exposed to 1,3-butadiene for 2 years

Toxicologic Pathology

Volumn 28, Issue 4, 2000, Pages 529-534

  Hong, Hue Hua L ^a   Devereux, Theodora R ^b   Melnick, Ronald L ^a   Moomaw, Cindy R ^a   Boorman, Gary A ^a   Sills, Robert C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b National Institute of Environmental and Health Sciences   (United States)

Author keywords

1,3 butadiene; Cardiac hemangiosarcoma; p53; ras

Indexed keywords

1,3 BUTADIENE; PROTEIN P53;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GENE MUTATION; GENOTOXICITY; HEART CANCER; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANIMALS; BUTADIENES; CELL CYCLE; FEMALE; GENES, P53; GENES, RAS; HEART NEOPLASMS; HEMANGIOSARCOMA; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED STRAINS; MUTAGENS;

ANIMALIA; RODENTIA;

EID: 0033854665     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262330002800404     Document Type: Article

References (56)

1. Andersson M. Jonsson M., Nielsen LL, Vyberg M., Visfeldt J. Storm HH, Wallin H. (1995). Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles. Cancer Epidemiol Biomark Prev 4: 765-770.
2. Barbin A., Froment O., Boivin S., Marion M., Belpoggi F., Maltoni C., Montesano R. (1997). p53 gene mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res 57: 1695-1698.
3. Belinsky SA, Devereux TR, Foley JF, Maronpot RR, Anderson MW (1992). Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 52: 3164-3173.
4. Chung FL, Wang M., Rivenson A., Iatropoulos MJ, Reinhardt JC, Pittman B., Ho CT, Amin SG (1998). Inhibition of lung carcinogenesis by black tea in fischer rats treated wtih a tobacco-specific carcinogen: Caffeine as an important constituent. Cancer Res 58: 4096-4101.
5. Citti L., Gervasi PG, Turchi G., Bellucci G., Bianchini R. (1984). The reaction of 3,4-epoxy-1-butene with deoxyguanosine and DNA in vitro: Synthesis and characterization of the main adducts. Carcinogenesis 5: 47-52.
6. Cochrane JE, Skopek TR (1994). Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1,2-epoxybutene and diepoxybutane at the hprt locus in splenic T cells from exposed B6C3F1 mice. Carcinogenesis 15: 719-723.
7. Crawford JM (1994). The liver and the biliary tract. In: Robbins Pathologic Basis of Disease, Cotran RS, Robbins SL, Kumar, V (eds). W. B. Saunders, Philadelphia, p 87.
8. deMeester C., Poncelet F., Roberfroid M., Mercier M. (1978). Matagenicity of butadiene and butadiene monoxide. Biochem Biophys Res Commn 80: 298.
9. Denissenko MF, Pao A., Tang M., Pfeifer GP (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430-432.
10. Devereux TR, Anderson MW, Belinsky SA (1991). Role of ras protooncogene activation in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse. Carcinogenesis 12: 299-303.
11. Devereux TR, Foley JF, Maronpot RR, Kari F., Anderson MW (1993). Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride. Carcinogenesis 14: 795-801.
12. Duddy SK, Gorospe SM, Bleavins MR, de la Iglesia FA (1999). Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol 160: 133-140.
13. Duddy SK, Parker RF, Bleavins MR, Gough AW, Rowse PE, Gorospe S., Dethloff LA, de la Inglesia FA (1999). p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicol Appl Pharmacol 156: 106-112.
14. Goodrow T., Reynolds S., Maronpot R., Anderson M. (1990). Activation of K-ras by codon 13 mutations in C57BL/6 × C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res 50: 4818-4823.
15. Goodrow TL, Nichols WW, Storer RD, Anderson MW, Maronpot RR (1994). Activation of H-ras is prevalent in 1,3-butadiene-induced and spontaneously occurring murine Harderian gland tumors. Carcinogenesis 15: 2665-2667.
16. Greenblatt MS, Bennett WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
17. Harvey M., McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A., Donehower LA (1993). Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5: 225-229.
18. Hegi ME, Soderkvist P. Foley JF. Schoonhoven R., Swenberg JA, Kari F., Maronpot R., Anderson MW, Wiseman RW (1993). Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis 14: 803-810.
19. Hollstein M., Marion MJ, Lehman T., Welsh J., Harris CC, Martel-Planche G., Kusters I., Montesano R. (1994). p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15: 1-3.
20. Hong HL, Devereux TR, Roycroft JH, Boorman GA, Sills RC (1998). Frequency of ras mutations in liver neoplasms from B6C3F1 mice exposed to tetrafluoroethylene for two years. Toxicol Pathol 26: 646-650.
21. Hongyo T., Buzard GS, Calvert RJ, Weghorst CM (1993). “Cold SSCP”: A simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res 21: 3637-3642.
22. Hsu IC, Metcalf RA, Sun T., Welsh JA, Wang NJ, Harris CC (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428.
23. Hsu SM, Raine L., Fanger H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580.
24. Huff J., Cirvello J., Haseman J., Bucher J. (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ Health Perspect 93: 247-270.
25. Huff JE, Melnick RL, Solleveld HA, Haseman JK, Powers M., Miller RA (1985). Multiple organ carcinogenicity of 1,3-butadiene in B6C3F1 mice after 60 weeks of inhalation exposure. Science 227: 548-549.
26. Hussain SP, Harris CC (1998). Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023-4037.
27. Koivisto P., Adler I., Pacchierotti F., Peltonen K. (1998). DNA adducts in mouse testis and lung after inhalation exposure to 1,3-butadiene. Mutat Res 397: 3-10.
28. La DK, Swenberg JA (1996). DNA adducts: Biological markers of exposure and potential applications to risk assessment. Mutat Res 365: 129-146.
29. Loeb LA, Christians FC (1996). Multiple mutations in human cancers. Mutat Res 350: 279-286.
30. Malvoisin E., Lhoest G., Poncelet F., Roberfroid M., Mercier M. (1979). Identification and quantitation of 1,2-expoybutene as the primary metabolite of 1,3-butadiene. J Chromatogr 178: 419-425.
31. Malvoisin E., Roberfroid M. (1982). Hepatic microsomal metabolism of 1,3-butadiene. Xenobiotia 12: 137-144.
32. Marion MJ, Froment O., Trepo C. (1991). Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog 4: 450-454.
33. Melnick RL, Huff J., Chou BJ, Miller RA (1990). Carcinogenicity of 1,3-butadiene in C57BL/6 × C3HF1 mice at low exposure concentrations. Cancer Res 50: 6592-6599.
34. Melnick RL, Kohn, MC (1995). Mechanistic data indicate that 1,3-butadiene is a human carcinogen. Carcinogenesis 16: 157-163.
35. Melnick RL, Sills RC, Portier CJ, Roycroft JH, Chou BJ, Brunbein SL, Miller RA (1999). Chronic toxicity and carcinogenicity of inhaled chloroprene (2-chloro-1,3,-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice. Carcinogenesis 20: 867-878.
36. Pomerantz J., Schreiber-Agus N., Liegeois NJ, Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee HW, Cordon-Cardo C., DePinho RA (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
37. Przygodzki RM, Finkelstein SD, Keohavong P., Zhu D., Bakker A., Swalsky PA, Soini Y., Ishak KG, Bennett WP (1997). Sporadic and thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. Lab Invest 76: 153-159.
38. Rao GN, Collins BJ, Giles HD, Heath JE, Foley JF, May RD, Buckley LA (1996). Carcinogenicity of 2’,3’-dideoxycytidine in mice. Cancer Res 56: 4666-4672.
39. Rodenhuis S. (1992). ras and human tumors. Cancer Biol 3: 241-247.
40. Saiki RK, Gelfand DH, Stoffel S., Scharf SJ, Higuchi R., Horn GT, Mullis KB, Erlich HA (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239: 487-490.
41. Schmidt U., Loeser E. (1985). Species differences in the formation of butadiene monoxide from 1,3-butadiene. Arch Toxicol 57: 222-225.
42. Selzer RR, Elfarra AA (1999). In vitro reactions of butadiene monoxide with single- and double-stranded DNA: Characterization and quantitation of several purine and pyrimidine adducts. Carcinogenesis 20: 285-292.
43. Shibata D. (1994). Extraction of DNA from paraffin-embedded tissue for analysis by polymerase chain reaction: New tricks from an old friend. Hum Pathol 25: 561-563.
44. Sills RC, Boorman GA, Neal JE, Hong HL, Devereux TR (1999). Mutations in ras genes in experimental tumours of rodents. In: The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation, McGregor DB, Rice JM, Venitt S (eds). International Agency for Research on Cancer, Lyon, France, pp 55-86.
45. Sills RC, Hong HL, Greenwell A., Herbert RA, Boorman GA, Devereux TR (1995). Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis 16: 1623-1628.
46. Sills RC, Hong HL, Melnick RL, Boorman GA, Devereux TR (1999). High frequency of codon 61 K-ras A to T transversions in lung and Harderian gland neoplasms of B6C3F1 mice exposed to chloroprene (2-chloro-1,3-butadiene) for 2-years, and comparisons with the structurally related chemicals isoprene and 1,3-butadiene. Carcinogenesis 20: 657-662.
47. Sisk SS, Pluta LJ, Bond JA, Recio L. (1994). Molecular analysis of lacI mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis 15: 471-477.
48. Soini Y., Welsh JA, Ishak KG, Bennett WP (1995). p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis 16: 2879-2881.
49. Steen A., Meyer KG, Recio L. (1997). Analysis of hprt mutations occurring in human TK6 lymphoblastoid cells following exposure to 1,2,3,4-diepoxybutane. Mutagenesis 12: 61-67.
50. Strauss BS (1997). Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18: 1445-1452.
51. Sukumuar S., Barbacid M. (1990). Specific patterns of oncogene activation in transplacentally induced tumors. Proc Natl Acad Sci USA 87: 718-722.
52. Trukhanova LS, Hong HL, Sills RC, Bowser AD, Gaul B., Boorman GA, Turusov VS, Devereux TR, Dixon D. (1998). Predominant p53 G to A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethylhydrazine. Toxicol Pathol 26: 367-374.
53. Wiseman RW, Cochran C., Dietrich W., Lander E., Soderkvist P. (1994). Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: Frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc Natl Acad Sci USA 91: 3759-3763.
54. Wright DK, Manos MM (1990). Sample preparation from paraffin-embedded tissues. In: PCR Protocols: A Guide to Methods and Applications, Innis MA, Gelfand DH, Sninsky JJ, White TJ, (eds). Academic Press, San Diego, CA, pp 153-158.
55. Zhuang S., Cochran C., Goodrow T., Wiseman R., Soderkvist P. (1997). Genetic alterations of p53 and ras genes in 1,3-butadiene-and 2’,3’-dideoxycytidine-induced lymphomas. Cancer Res 57: 2710-2714.
56. Zhuang S-M., Eklund LK, Cochran C., Rao GN, Wiseman RW, Soderkvist P. (1996). Allelotype analysis of 2’,3’-dideoxycytidine and 1,3-butadiene-induced lymphomas in B6C3F1 mice. Cancer Res 56: 3338-3343.